Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$33.75
neg -0.22
-0.65%
Today's Range: 33.62 - 34.12 | TEVA Avg Daily Volume: 10,385,800
Last Update: 01/17/17 - 4:00 PM EST
Volume: 9,970,844
YTD Performance: -6.29%
Open: $34.05
Previous Close: $33.97
52 Week Range: $33.56 - $64.31
Oustanding Shares: 1,015,000,000
Market Cap: 34,479,550,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 8 10 10
Moderate Buy 1 1 2 2
Hold 9 8 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.19 2.00 1.68 1.59
Latest Dividend: 0.29
Latest Dividend Yield: 3.40%
Dividend Ex-Date: 12/01/16
Price Earnings Ratio: 6.74
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
6.74 19.60 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-23.28% -45.89% -18.01%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.33 $n.a. $5.05 $5.03
Number of Analysts 1 0 2 2
High Estimate $1.33 $n.a. $5.05 $5.06
Low Estimate $1.33 $n.a. $5.04 $5.00
Prior Year $1.28 $1.18 $5.42 $5.05
Growth Rate (Year over Year) 3.91% n.a.% -6.92% -0.30%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

David Katz

 | Jan 11, 2017 | 8:00 AM EST
This pharma company is still making lots of money and its stock is too cheap to pass up.
By

Bret Jensen

 | Jan 6, 2017 | 11:55 AM EST
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid …
RMPIA
By

Bret Jensen

 | Jan 3, 2017 | 11:00 AM EST
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
RMPIA
By

Bret Jensen

 | Dec 27, 2016 | 11:44 AM EST
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
RMPIA
By

Bret Jensen

 | Dec 27, 2016 | 11:00 AM EST
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
RMPIA
By

Bret Jensen

 | Dec 16, 2016 | 8:58 AM EST
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.
By

Paul Price

 | Dec 8, 2016 | 8:00 AM EST
Here are stocks with solid fundamentals at some of the best absolute entry points in years.
By

Bruce Kamich

 | Dec 6, 2016 | 11:04 AM EST
Wait for a bounce and then a retest before stepping up to buy.
RMPIA
By

Bret Jensen

 | Nov 28, 2016 | 11:00 AM EST
Small-caps could also benefit from abating tax-loss selling.
RMPIA
By

Real Money

 | Nov 25, 2016 | 2:00 PM EST
'Milestone payments' could boost deal's $125 million announced price.
Shares of PG area trading at new January highs this afternoon.  The stock is up over ...
Market slightly down across the board to start the holiday shortened trading week.  N...
This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both re...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Ch...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.